Hims & Her Health It has acquired Trybe Labs, a home lab testing facility in New Jersey, announced Wednesday.
The deal will allow telemedicine companies Provide blood at home And conduct more comprehensive pre-processing tests on users.
“Acquiring wealthy data allows us to deepen insights that providers can use on the platform to guide clinical decisions for each patient,” said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers.
“At-home lab testing is a more exciting step to improve the country’s individuals and comprehensive care clients should expect,” Carroll added.
Hims did not disclose the terms of the deal, but said it was funded through cash funds. The company told CNBC that when customers offer products next year, pricing for new testing options will be shared.
The Hims & Hers acquisition will compete for blood painting services such as Labcorp and Quest Diagnostics.
The startup expanded its services less than a year after it started offering Compound GLP-1 Weight loss pills. It recently targeted the pharmaceutical industry when Hims & hers saw herself as a replacement for cheaper alternatives Super Bowl Advertisingsaying the industry is “price for profit, not for patients”.
“The healthcare customers expect and deserve is on-demand care that provides on-demand treatments designed specifically for them,” Dr. Carroll said.
While the company’s stock is prone to volatility, Wall Street bought it this year: Stocks soared 141% in 2025, and as of the end of Tuesday, the stock entered trading. The stock soared 15% in Wednesday’s trading after the trading announcement.
The company said the new acquisition will increase testing capacity for LDL cholesterol, lipoprotein (A), cholesterol and apolipoprotein. It will also expand the company’s ability to provide care and treatment in a variety of diseases, including low testosterone and perimenopause and menopause support.
The Tasso+ device is a blood prick that collects all liquid blood samples. Multiple standard collection tubes are compatible. Tasso+ is FDA Class II Lancet 510 (K) transparent. ”
Courtesy: Tasso Inc.
Will be provided for HIMS users Blood willow sac Provided by the Family Diagnostic Testing Company Tasso. The Lancet is a disposable device that collects entire liquid blood samples and removes them for pre-market use by the FDA.
The user secures the device to the upper arm and presses a button to trigger the lancet to pierce the skin and draws a small amount of blood in the microtubule.
Providers on the platform will use the collected information as part of determining a patient’s treatment plan.
Hims & Hers said it will use data from blood work (deleting patient identities) to accelerate its AI-driven healthcare development.
Clarification: This story is updated to reflect that the new testing service will help the company’s perimenopause treatment care.
